Time course of microbiologic outcome and gene expression in Candida albicans during and following in vitro and in vivo exposure to fluconazole

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 4, 2006, Pages 1311-1319

  Lepak, A ^a   Nett, J ^a   Lincoln, L ^a   Marchillo, K ^a   Andes, D ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CDR1 GENE; CDR2 GENE; CELL POPULATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA MICROARRAY; DNA REPAIR; DNA SYNTHESIS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG HALF LIFE; ERG11 GENE; FUNGAL CELL; FUNGAL GENE; FUNGUS GROWTH; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; RNA ISOLATION; STRESS; TIME SERIES ANALYSIS; TRANSCRIPTION REGULATION; UPREGULATION;

ANIMALS; ANTIFUNGAL AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CANDIDA ALBICANS; FLUCONAZOLE; FUNGAL PROTEINS; GENE EXPRESSION PROFILING; MEMBRANE TRANSPORT PROTEINS; MICE; MICROBIAL SENSITIVITY TESTS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, MESSENGER;

EID: 33645755409     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.4.1311-1319.2006     Document Type: Article

References (43)

1. Agarwal, A. K., P. D. Rogers, S. R. Baerson, M. R. Jacob, K. S. Barker, J. D. Cleary, L. A. Walker, D. G. Nagle, and A. M. Clark. 2003. Genome-wide expression profiling of the response to polyene, pyrimidine, azole, and echinocandin antifungal agents in Saccharomyces cerevisiae. J. Biol. Chem. 278:34998-35015.
2. Andes, D., A Lepak, A. Pitula, K. Marchillo, and J. Clark. 2005. A simple approach for estimating gene expression in Candida albicans directly from a systemic infection site. J. Infect. Dis. 192:893-900.
3. Andes, D., and M. van Ogtrop. 1999. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis model. Antimicrob. Agents Chemother. 43:2116-2120.
4. Andes, D. 2003. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob. Agents Chemother. 47:1179-1186.
5. Andes, D., T. Stamstad, and R. Conklin. 2001. Pharmacodynamics of amphotericin B in a neutropenic mouse disseminated candidiasis model. Antimicrob. Agents Chemother. 45:922-926.
6. Bammert, G. F., and J. M. Fostel. 2000. Genome-wide expression patterns in Saccharomyces cerevisiae: comparison of drug treatments and genetic alterations affecting biosynthesis of ergosterol. Antimicrob. Agents Chemother. 44:1255-1265.
7. Barmada, S., S. Kohlhepp, J. Leggett, R. Dworkin, and D. Gilbert. 1993. Correlation of tobramycin-induced inhibition of protein synthesis with postantibiotic effect in Escherichia coli. Antimicrob. Agents Chemother. 37:2678-2683.
8. Braun, B. R., M. van het Hoog, C. d'Enfert, C. M. Martchenko, J. Dungan, A. Kuo, D. O. Inglis, M. A. Uhl, H. Hogues, M. Berriman, M. Lorenz, A. Levitin, U. Oberholzer, C. Bachewich, D. Harcus, A. Marcil, D. Dignard, T. Iouk, R. Zito, L. Frangeul, F. Tekaia, K. Rutherford, E. Wang, C. A. Munro, S. Bates, N. A. Gow, L. L. Hoyer, G. Köhler, J. Morscbhäuser, G. Newport, S. Znaidi, M. Raymond, B. Turcotte, G. Sherlock, M. Costanzo, J. Ibmels, J. Berman, D. Sanglard, N. Agabian, A. P. Mitchell, A. D. Johnson, M. Whiteway, and A. Nantel. 2005. A human-curated annotation of the Candida albicans genome. PLOS Genet. 1:e1.
9. Bundtzen, R. W., A. U. Gerber, D. L. Cohn, and W. A. Craig. 1981. Post-antibiotic suppression of bacterial growth. Rev. Infect. Dis. 3:28-37.
10. Bustin, S. A. 2000. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J. Mol. Endocrinol. 25:169-193.
11. Champney, W. S., and C. L. Tober. 1999. Molecular investigation of the postantibiotic effects of clarithromycin and erythromycin on Staphylococcus aureus cells. Antimicrob. Agents Chemother. 43:1324-1328.
12. Cowen, L. E., A. Nantel, M. S. Whiteway, D. Y. Thomas, D. C. Tessier, L. M. Kohn, and J. B. Anderson. 2002. Population genomics of drug resistance in Candida albicans. Proc. Natl. Acad. Sci. USA 99:9284-9289.
13. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
14. Craig, W. A., and S. Gudmundsson. 1996. Postantibiotic effect, p. 296-329. In V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. Williams and Wilkins, Baltimore, Md.
15. DeBacker, M. D., T. Ilyina, X. J. Ma, S. Vandoninck, W. H. Luyten, and H. Vanden Bossche. 2001. Genomic profiling of the response of Candida albicans to itraconazole treatment using a DNA microarray. Antimicrob. Agents Chemother. 45:1660-1670.
16. Ernst, E., M. E. Klepser, and M. A. Pfaller. 2000. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob. Agents Chemother. 44:1108-1111.
17. Gottfredsson, M., H. Erlendsdottir, A. Gudmundsson, and S. Gudmundsson. 1995. Different patterns of bacterial DNA synthesis during postantibiotic effect. Antimicrob. Agents Chemother. 39:1314-1319.
18. Gottfredsson, M., H. Erlendsdottir, R. Kolka, A. Gudmundsson, and S. Gudmundsson. 1993. Ultrastructural alterations of bacteria during the postantibiotic effect. Chemotherapy 39:153-162.
19. Gottfredsson, M., H. Erlendsdottir, A. Sigfusson, and S. Gudmundsson. 1998. Characteristics and dynamics of bacterial populations during postantibiotic effect determined by flow cytometry. Antimicrob. Agents Chemother. 42:1005-1011.
20. Guan, L., R. M. Blumenthal, and J. C. Burnham. 1992. Analysis of macromolecular biosynthesis to define the quinolone-induced postantibiotic effect in Escherichia coli. Antimicrob. Agents Chemother. 36:2118-2124.
21. Hingamp, J., J. Quackenbush, G. Sherlock, P. Spellman, C. Stoeckert, J. Aach, W. Ansorge, C. A. Ball, H. C. Causton, T. Gaasterland, P. Glenisson, F. C. P. Holstege, I. F. Kim, V. Markowitz, J. C. Matese, H. Parkinson, A. Robinson, U. Sarkans, S. Schulze-Kremer, J. Stewart, R. Taylor, J. Vilo, and M. Vingron. 2001. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat. Genet. 29:365-371.
22. Karababa, M., A. T. Coste, B. Rognon, J. Bille, and D. Sanglard. 2004. Comparison of gene expression profiles of Candida albicans azole-resistant clinical isolates and laboratory strains exposed to drugs inducing multidrug transporters. Antimicrob. Agents Chemother. 48:3064-3079.
23. Liu, T. T., R. E. Lee, K. S. Barker, R. E. Lee, L. Wei, R. Homayouni, and P. D. Rogers. 2005. Genome-wide expression profiling of the response to azole, polyene, echinocandin, and pyrimidine antifungal agents in Candida albicans. Antimicrob. Agents Chemother. 49:2226-2236.
24. Livak, K. J., S. J. Flood, J. Marmaro, W. Giusti, and K. Deetz. 1995. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Methods Appl. 4:357-362.
25. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2ΔCT method. Methods 25:402-408.
26. Losberger, C., and J. F. Ernst. 1989. Sequence of Candida albicans gene encoding actin. Nucleic Acids Res. 17:9488.
27. Louie, A., G. L. Drusano, P. Banerjee, Q. F. Liu, P. Kaw, M. Shayegani, H. Taber, and M. H. Miller. 1998. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob. Agents Chemother. 42:1105-1109.
28. Lyons, C. N., and T. C. White. 2000. Transcriptional analyses of antifungal drug resistance in Candida albicans. Antimicrob. Agents Chemother. 44:2296-2303.
29. Moore, R. D., P. S. Lietman, and C. R. Smith. 1987. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J. Infect. Dis. 155:93-99.
30. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing for yeast. Accepted standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
31. National Research Council Committee on the Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, Commission on Life Sciences. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, D.C.
32. Nosanchuk, J. D., W. Cleare, S. P. Franzot, and A. Casadevall. 1999. Amphotericin B and fluconazole affect cellular charge, macrophage phagocytosis, and cellular morphology of Cryptococcus neoformans at subinhibitory concentrations. Antimicrob. Agents Chemother. 43:233-239.
33. Nugent, K. M., and K. R. Couchot. 1986. Effects of sublethal concentrations of amphotericin B on Candida albicans. J. Infect. Dis. 154:665-669.
34. Prasad, R., P. De Wergifosse, A. Goffeau, and E. Balzi. 1995. Molecular cloning and characterization of a novel gene in Candida albicans, CDR1, conferring multiple drug resistance to drugs and antifungals. Curr. Genet. 27:320-329.
35. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
36. Sanglard, D., F. Ischer, M. Monod, and J. Bille. 1997. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 143:405-416.
37. Schmitt, M. E., T. A. Brown, and B. L. Trumpower. 1990. A rapid and simple method for preparation of RNA from Saccharomyces cerevisiae. Nucleic Acids Res. 18:3091-3092.
38. Tornqvist, I. O., S. E. Holm, and O. Cars. 1990. Pharmacodynamic effects of subinhibitory antibiotic concentrations. Scand. J. Infect. Dis. 74(Suppl.):94-101.
39. Turnidge, J. D., S. Gudmundsson, B. Vogelman, and W. A. Craig. 1994. The postantibiotic effect of antifungal agents against common pathogenic yeasts. J. Antimicrob. Chemother. 34:83-92.
40. Vogelman, B., S. Gudmundsson, J. Turnidge, J. Leggett, and W. A. Craig. 1988. In vivo postantibiotic effect in a thigh infection in neutropenic mice. J. Infect. Dis. 157:287-298.
41. White, T. C., K. A. Marr, and R. A. Bowden. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-402.
42. White, T. C. 1997. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 41:1482-1487.
43. Wickens, H. J., R. J. Pinney, D. J. Mason, and V. A. Gant. 2000. Flow cytometric investigation of filamentation, membrane patency, and membrane potential in Escherichia coli following ciprofloxacin exposure. Antimicrob. Agents Chemother. 44:682-687.